strain gage transducers mlt0699 Search Results


transducer  (ADInstruments)
96
ADInstruments transducer
The decrease in NO levels in vivo following the ingestion of HFD and L-NAME decreased the activity of the NO-sGC-cGMP pathway. cGMP-activated PKG has hypotensive, anti-inflammatory, and anti-fibrotic effects; therefore, decreased activity of the NO-sGC-cGMP pathway may lead to inflammation, hypertrophy, and apoptosis, leading to the development of HFpEF. Furthermore, the decrease in NO levels in vivo converts Ang I to Ang II; hence, a decrease in NO activates RAS. Ang II increased by RAS activity increases TGF-β expression, which consequently activates the MAPK signaling pathway, leading to fibroblast proliferation, ECM overdeposition, and fibrosis. Ang II also activates the PI3K-Akt and JAK-STAT signaling pathways, which may trigger inflammation, hypertrophy, and apoptosis, leading to HFpEF development. Early administration of the RAS inhibitors Cap and Sac/Val may suppress downstream signaling by inhibiting RAS, thereby reducing inflammation and fibrosis and preventing the onset of HFpEF. NO: nitric oxide; HFD: high-fat diet; L-NAME: NG-Nitro-L-arginine methyl ester; sGC: soluble guanylate cyclase; cGMP: cyclic guanosine monophosphate; PKG: protein kinase G; Ang I: angiotensin I; Ang II: angiotensin II; RAS: renin-angiotensin system; TGF-β: transforming growth factor-β; MAPK: mitogen-activated protein kinase; ECM: extracellular matrix; PI3K: phosphatidylinositol-3 kinase; Akt: serine/threonine protein kinase; JAK: janus kinase; STAT: signal <t>transducer</t> and activator of transcription.
Transducer, supplied by ADInstruments, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/strain+gage+transducers+mlt0699/Disposable+BP+Transducer/pmc12981474-61-7-11
Average 96 stars, based on 1 article reviews
transducer - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
mlt0699 transducer  (POWERLAB INC)
90
POWERLAB INC mlt0699 transducer
The decrease in NO levels in vivo following the ingestion of HFD and L-NAME decreased the activity of the NO-sGC-cGMP pathway. cGMP-activated PKG has hypotensive, anti-inflammatory, and anti-fibrotic effects; therefore, decreased activity of the NO-sGC-cGMP pathway may lead to inflammation, hypertrophy, and apoptosis, leading to the development of HFpEF. Furthermore, the decrease in NO levels in vivo converts Ang I to Ang II; hence, a decrease in NO activates RAS. Ang II increased by RAS activity increases TGF-β expression, which consequently activates the MAPK signaling pathway, leading to fibroblast proliferation, ECM overdeposition, and fibrosis. Ang II also activates the PI3K-Akt and JAK-STAT signaling pathways, which may trigger inflammation, hypertrophy, and apoptosis, leading to HFpEF development. Early administration of the RAS inhibitors Cap and Sac/Val may suppress downstream signaling by inhibiting RAS, thereby reducing inflammation and fibrosis and preventing the onset of HFpEF. NO: nitric oxide; HFD: high-fat diet; L-NAME: NG-Nitro-L-arginine methyl ester; sGC: soluble guanylate cyclase; cGMP: cyclic guanosine monophosphate; PKG: protein kinase G; Ang I: angiotensin I; Ang II: angiotensin II; RAS: renin-angiotensin system; TGF-β: transforming growth factor-β; MAPK: mitogen-activated protein kinase; ECM: extracellular matrix; PI3K: phosphatidylinositol-3 kinase; Akt: serine/threonine protein kinase; JAK: janus kinase; STAT: signal <t>transducer</t> and activator of transcription.
Mlt0699 Transducer, supplied by POWERLAB INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/strain+gage+transducers+mlt0699/pressure+transducer+mlt+0699/pmc02519190-53-6-12
Average 90 stars, based on 1 article reviews
mlt0699 transducer - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


The decrease in NO levels in vivo following the ingestion of HFD and L-NAME decreased the activity of the NO-sGC-cGMP pathway. cGMP-activated PKG has hypotensive, anti-inflammatory, and anti-fibrotic effects; therefore, decreased activity of the NO-sGC-cGMP pathway may lead to inflammation, hypertrophy, and apoptosis, leading to the development of HFpEF. Furthermore, the decrease in NO levels in vivo converts Ang I to Ang II; hence, a decrease in NO activates RAS. Ang II increased by RAS activity increases TGF-β expression, which consequently activates the MAPK signaling pathway, leading to fibroblast proliferation, ECM overdeposition, and fibrosis. Ang II also activates the PI3K-Akt and JAK-STAT signaling pathways, which may trigger inflammation, hypertrophy, and apoptosis, leading to HFpEF development. Early administration of the RAS inhibitors Cap and Sac/Val may suppress downstream signaling by inhibiting RAS, thereby reducing inflammation and fibrosis and preventing the onset of HFpEF. NO: nitric oxide; HFD: high-fat diet; L-NAME: NG-Nitro-L-arginine methyl ester; sGC: soluble guanylate cyclase; cGMP: cyclic guanosine monophosphate; PKG: protein kinase G; Ang I: angiotensin I; Ang II: angiotensin II; RAS: renin-angiotensin system; TGF-β: transforming growth factor-β; MAPK: mitogen-activated protein kinase; ECM: extracellular matrix; PI3K: phosphatidylinositol-3 kinase; Akt: serine/threonine protein kinase; JAK: janus kinase; STAT: signal transducer and activator of transcription.

Journal: PLOS One

Article Title: Early administration of renin–angiotensin system inhibitors improves survival and cardiac remodeling in heart failure with preserved ejection fraction

doi: 10.1371/journal.pone.0339600

Figure Lengend Snippet: The decrease in NO levels in vivo following the ingestion of HFD and L-NAME decreased the activity of the NO-sGC-cGMP pathway. cGMP-activated PKG has hypotensive, anti-inflammatory, and anti-fibrotic effects; therefore, decreased activity of the NO-sGC-cGMP pathway may lead to inflammation, hypertrophy, and apoptosis, leading to the development of HFpEF. Furthermore, the decrease in NO levels in vivo converts Ang I to Ang II; hence, a decrease in NO activates RAS. Ang II increased by RAS activity increases TGF-β expression, which consequently activates the MAPK signaling pathway, leading to fibroblast proliferation, ECM overdeposition, and fibrosis. Ang II also activates the PI3K-Akt and JAK-STAT signaling pathways, which may trigger inflammation, hypertrophy, and apoptosis, leading to HFpEF development. Early administration of the RAS inhibitors Cap and Sac/Val may suppress downstream signaling by inhibiting RAS, thereby reducing inflammation and fibrosis and preventing the onset of HFpEF. NO: nitric oxide; HFD: high-fat diet; L-NAME: NG-Nitro-L-arginine methyl ester; sGC: soluble guanylate cyclase; cGMP: cyclic guanosine monophosphate; PKG: protein kinase G; Ang I: angiotensin I; Ang II: angiotensin II; RAS: renin-angiotensin system; TGF-β: transforming growth factor-β; MAPK: mitogen-activated protein kinase; ECM: extracellular matrix; PI3K: phosphatidylinositol-3 kinase; Akt: serine/threonine protein kinase; JAK: janus kinase; STAT: signal transducer and activator of transcription.

Article Snippet: The cannula was then connected to a transducer (MLT0670, BP transducer, AD Instruments, Oxford, UK), and blood pressure was continuously monitored for 10 min using the PowerLab® system (AD Instruments), with the average value calculated [ ].

Techniques: In Vivo, Activity Assay, Expressing, Protein-Protein interactions